GUANGDONG TAIENKANG PHARMACEUTICAL CO., LTD. Guangdong Taienkang Pharmaceutical Co., Ltd. Share Price
Equities
301263
CNE1000058X0
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.86 CNY | -0.39% |
|
-1.00% | -21.25% |
| Sales 2022 | 783M 108M 9.01B | Sales 2023 | 761M 105M 8.75B | Capitalization | 6.95B 958M 79.87B |
|---|---|---|---|---|---|
| Net income 2022 | 175M 24.12M 2.01B | Net income 2023 | 160M 22.05M 1.84B | EV / Sales 2022 | 8.5 x |
| Net cash position 2022 | 1.02B 141M 11.77B | Net cash position 2023 | 531M 73.2M 6.11B | EV / Sales 2023 | 8.43 x |
| P/E ratio 2022 |
41.1
x | P/E ratio 2023 |
43
x | Employees | 931 |
| Yield 2022 |
2.15% | Yield 2023 |
1.84% | Free-Float | 44.57% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.39% | ||
| 1 week | -1.00% | ||
| Current month | -6.47% | ||
| 1 month | -10.01% | ||
| 3 months | -13.92% | ||
| 6 months | -26.72% | ||
| Current year | -21.25% |
1 week
12.70
13.50
1 month
12.5514.90
Current year
11.6516.46
1 year
11.6523.99
3 years
11.6523.99
5 years
11.6523.99
10 years
11.6523.99
| Managers | Title | Age | Since |
|---|---|---|---|
Han Jie Zheng
CEO | Chief Executive Officer | 61 | 01/99/01 |
Gui Xi Zhou
DFI | Director of Finance/CFO | 37 | 02/22/02 |
Ting Li
BRD | Director/Board Member | 41 | 01/19/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Liang
BRD | Director/Board Member | 52 | 30/22/30 |
Yi Ping Rui
BRD | Director/Board Member | 70 | 03/18/03 |
Han Jie Zheng
CEO | Chief Executive Officer | 61 | 01/99/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 12.86 | -0.39% | 1,093,540 |
| 14/24/14 | 12.91 | -1.15% | 1,351,740 |
| 13/24/13 | 13.06 | -2.03% | 1,606,340 |
| 12/24/12 | 13.33 | 0.00% | 1,707,127 |
End-of-day quote Shenzhen S.E., June 17, 2024
More quotes
Guangdong Taienkang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development and production of pharmaceutical products. The Company's businesses include agency operation, and sales of pharmaceutical products, medical devices and hygiene materials. The Company's main products include chemical medicines, external medicines, proprietary Chinese medicines, medical devices and hygiene materials. The Company is also engaged in the provision of medical technology services and technology transfer. The Company mainly conducts its businesses in the domestic market.
Sector
Pharmaceuticals
Calendar
27/08/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.25% | 751M | |
| +51.82% | 797B | |
| +40.85% | 628B | |
| -6.88% | 351B | |
| +16.95% | 323B | |
| +9.49% | 300B | |
| +17.08% | 244B | |
| +0.98% | 223B | |
| +5.30% | 163B | |
| -6.29% | 153B |
- Stock Market
- Equities
- 301263 Stock
